Moving Stocks: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Riverbed Technology, Inc. (NASDAQ:RVBD), eHealth, Inc. (NASDAQ:EHTH), IDEX Corporation (NYSE:IEX)

Merck (MRK) announced it’s buying the Cubist Pharmaceuticals Inc. (NASDAQ:CBST) for $102 per share. Cubist Pharmaceuticals Inc. does advanced antibiotic research and is noted for its research on superbugs — diseases that have developed immunity to antibiotic treatment. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) belongs to Healthcare sector. Its net profit margin is 5.60% and weekly performance is 0.94%. On last trading day company shares ended up … Continue reading Moving Stocks: Cubist Pharmaceuticals Inc. (NASDAQ:CBST), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Riverbed Technology, Inc. (NASDAQ:RVBD), eHealth, Inc. (NASDAQ:EHTH), IDEX Corporation (NYSE:IEX)

Big Movers : BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eastman Chemical Co. (NYSE:EMN), Pike Corporation (NYSE:PIKE), General Motors Company (NYSE:GM)

BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II unloaded 10,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $13.58, for a total transaction of $135,800.00. Following the completion of the transaction, the chief financial officer now directly owns 162,942 shares in the company, valued at approximately $2,212,752. BioCryst Pharmaceuticals, Inc. … Continue reading Big Movers : BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Eastman Chemical Co. (NYSE:EMN), Pike Corporation (NYSE:PIKE), General Motors Company (NYSE:GM)

Gilead Sciences GILD NASDAQ:GILD

Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both … Continue reading Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Bullish Stocks At NASDAQ: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Scientific Games Corp (NASDAQ:SGMS), Origin Agritech (NASDAQ:SEED), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) issued its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.04, American Banking News reports. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock performance was 11.02% in last session and finished the day at $2.82. Traded volume was 4,339,672 shares in the last session and the average volume of the … Continue reading Bullish Stocks At NASDAQ: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Scientific Games Corp (NASDAQ:SGMS), Origin Agritech (NASDAQ:SEED), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)